The molecular cytogenetics market is anticipated to grow significantly in the North American area as a result of enhanced healthcare infrastructure, effective government policies, a huge base of multinational firms, and an increase in genetic disorders. The Indiana Health Coverage Programme module covers chromosomal microarray analysis (CMA), also known as cytogenetic microarray analysis, which is determined to be medically necessary for diagnosing a genetic abnormality in children with apparent nonsyndromic cognitive developmental delay/intellectual delay (DD/ID) or autism spectrum disorder (ASD), according to the article published in May 2022.
The market for Molecular Cytogenetics is anticipated to reach US$ 4,211.4 million in 2023 and is projected to grow at a CAGR of 24.5% from 2023 to 2030.
Major Players in the Molecular Cytogenetics Industry:
1. Abbott Laboratories: Abbott produces and sells branded generic pharmaceuticals, adult and paediatric nutritional items, diagnostic tools, and testing kits. Pacemakers, implanted cardioverter defibrillators, neuromodulation tools, coronary stents, catheters, baby formula, adult dietary liquids, molecular diagnostic platforms, immunoassays, and point-of-care diagnostic tools are among the products. Built in 1888. American headquarters in North Chicago. Recent Acquisitions: Cephea Valve Technologies (Jan 2019), JETi (Sep 2021), Cardiovascular Systems (Feb 2023).
2. Agilent Technologies, Inc.: Agilent, which was first separated from Hewlett-Packard in 1999, has grown into a major player in the life sciences and diagnostics industries. With its three operating segments—life science and applied tools, cross lab (containing of consumables and services connected to life science and applied tools), and diagnostics and genomics—Agilent's measuring solutions currently serve a wide range of clients. The most recent acquisitions include Resolution Bioscience (Mar 2021), PSS Polymer Standards Service (Aug 2022), and Avida Biomed (Jan 2023).
3. Applied Spectral Imaging, Inc: Creator of gene modification methods that make use of skills in stem cells and genome editing to promote industrial biotechnology and next-generation biomedical research. Abcam plc, a leader in the development of life science reagents and technologies, was pleased to announce in 2020 that it had acquired the gene editing platform and oncology product line of Applied StemCell, Inc. (ASC) for use in life science research and diagnostic applications. ASC was founded in 2008 and has its headquarters in U.S
4. BI Biological Industries: Creator of an adaptable organ-on-chip platform that aims to unite biology and engineering. Biologists can gain direct access to the cell culture thanks to the company's platform's strong connection to a microfluidic channel via a porous membrane that can accommodate a wide range of tissue sample types. Founded 2016. Headquarter location: the Netherlands.
5. Bio-Rad Laboratories: With its headquarters in Hercules, California, Bio-Rad Laboratories creates, produces, and sells goods and services for the clinical diagnostics and life sciences industries. Built in 1952. United States headquarters. Recent acquisitions include Celsee Diagnostics (April 2020), PCR|ONE (Aug 2022), and Dropworks.
6. Thermo Fisher Scientific Inc.: Thermo Fisher Scientific sells reagents for life sciences, laboratory supplies, and equipment for diagnostics. Founded 1956. United States headquarters.
7. F. Hoffmann-La Roche Ltd.: Tasmar's rights to production, marketing, and distribution in the United States and a few other non-European Union areas. Parkinson's illness is managed with the medication tasmar. United States headquarters. For $449 million, Roche buys the biotech company Inflazome.
*Definition: Molecular cytogenetics is a study of genetic disorders using new technologies that combine cytogenetic and molecular techniques.
